Food Noise as a Missing Piece in Obesity Treatment

Obesity treatment has entered a new era with the widespread adoption of GLP-1 receptor agonists. A striking patient-reported phenomenon, the silencing of persistent, intrusive food thoughts, has emerged. This construct, formally defined as 'food noise', is measurable through validated instruments and resembles cognitive rumination more than physiological appetite. Recent consensus guidance calls for integrating nutritional and lifestyle strategies alongside GLP-1 therapy. However, no prior framework has positioned food noise as the central unifying construct linking pharmacological, culinary-behavioral, and digital monitoring approaches. This Perspective argues that sustainable obesity management requires treating food noise as a measurable therapeutic target across neurobiological, culinary-nutritional, and cognitive-behavioral dimensions. GLP-1 receptors are expressed throughout appetite-regulating and reward-processing circuitry. Merkel et al. identified an endogenous nucleus tractus solitarius (NTS)-to-ventral tegmental area (VTA) circuit in which GLP-1-secreting neurons increase GABAergic inhibition, attenuating dopaminergic reward-seeking activity and providing a plausible neurobiological substrate for food noise reduction during semaglutide and tirzepatide treatment. Cook (2026) further proposed that GLP-1 receptor agonists suppress default mode network hyperactivity, a mechanism through which mindfulness-based practices reduce food preoccupation. The critical problem is closure upon discontinuation, as food noise reliably returns within days to weeks, and the STEP 1 trial extension demonstrated approximately two-thirds weight regain within one year of semaglutide withdrawal. Three converging problems expose the limits of pharmacotherapy alone: access inequities, treatment adherence, and the need for comprehensive, integrated interventions.